A retrospective chart review study of patients treated in a hospital-based brexanolone program

Arch Womens Ment Health. 2025 May 2. doi: 10.1007/s00737-025-01588-9. Online ahead of print.

ABSTRACT

PURPOSE: Postpartum depression (PPD), the most common childbirth complication in the United States, can be treated using brexanolone, an intravenous form of allopregnanolone.

METHODS: This retrospective chart review study evaluated clinical outcomes of 64 postpartum women who received brexanolone infusion for PPD in a real-world setting.

RESULTS: Treatment was associated with improved depression and anxiety symptoms, and 71% of patients reported significant improvement in their PPD.

CONCLUSIONS: While further research is needed, this study supports brexanolone as an efficacious treatment for PPD.

PMID:40312466 | DOI:10.1007/s00737-025-01588-9